According to a new research report “Myelofibrosis (MF) Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, MF therapeutics currently exhibits a proliferating pipeline with 50+ therapeutic candidates.
MF Therapeutics Pipeline Insights
MF is an uncommon ailment described by the presence of excessive scar tissues in bone marrow that diminishes its hematopoietic potential. MF is the causes of a genetic mutation in the blood stem cells. However, the primary cause of this genetic mutation is clinically unidentified. Mutation in Janus Kinases 2 (JAK2), myeloproliferative leukemia virus oncogene (MPL), calreticulin (CALR), and tet methylcytosine dioxygenase 2 (TET2) are expected to cause this disorder. Symptoms of MF include fever, bone pain, excessive sweating, shortness of breath, and weakness. The other problems related with MF are immense pain in bones and joints, leukemia, and hypertension. The disease can be analyzed by performing tests including blood test, physical examination, hereditary test, bone marrow examination, computed tomography (CT) scan, and magnetic resonance imaging (MRI) scans.
Jakafi (Incyte Corporation) is the only drug approved by the U.S. Food and Drug Administration (USFDA) for the treatment of MF. The other treatment regimens include chemotherapy, radiation therapy, surgical removal of spleen, and stem cell therapy.
Insights into Pipeline Segments
According to the research findings, majority of pipeline drug candidates are being developed for topical administration. It has been found that the topical route of administration is easy to use and non-invasive, and ensures high level of patient’s satisfaction.
Positive Clinical Trial Results are Expected to Drive MF Therapeutics Pipeline
Companies that are involved in developing therapeutics for MF have shown positive clinical results in various phases of drug development. For instance, in August 2016, CTI BioPharma Corp. announced positive data of phase III trial of pacritinib for the treatment of patients with MF. The results of the study concluded that treatment with pacritinib has a favorable safety and tolerability profile. The study also recorded efficacy of pacritinib with a 35% spleen volume reduction (SVR) from the baseline.
Browse Detailed Report at:https://www.pharmaproff.com/report/myelofibrosis-therapeutics-pipeline-analysis
Global Market for MF Therapeutics is Expected to Increase Statistically in the next 10 years
An analysis done for pipeline products demonstrated that pacritinib, INC424, and Ruxolitinib are the leading product candidates for the treatment of MF. With the approval of these candidates and rising development of other pipeline products will cater the growth of the MF therapeutics market in the next 10 years.
Incyte Corporation, CTI BioPharma Corp., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Novartis International AG, AbbVie Inc., Nippon Shinyaku Co. Ltd., Celgene Corporation, Sierra Oncology Inc., Promedior Inc., Imago BioSciences, Samus Therapeutics Inc., Constellation Pharmaceuticals Inc., and Kartos Therapeutics Inc. are some of the key players involved in the development of therapeutic drugs indicated for the treatment of MF.
MF Therapeutics Pipeline Analysis
The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of MF. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the MF therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to MF.